Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
EXG-34217 by Elixirgen Therapeutics for Bone Disorders: Likelihood of Approval
EXG-34217 is under clinical development by Elixirgen Therapeutics and currently in Phase I for Bone Disorders. According to GlobalData, Phase...